TREATMENT OUTCOMES FOR CHILDREN WITH ANXIETY DISORDERS

本申请表推荐莫伊拉·A·林恩医学博士获得宾夕法尼亚大学以患者为导向的研究职业发展奖。该计划的目标包括：1)支持我发展成为一名独立的研究科学家；2)支持和加强我作为儿童和青少年焦虑症研究人员的发展；3)发展我利用临床经验设计和执行方案的能力，该方案将回答拟议的研究问题；以及4)根据获奖期间所做的研究，为准备RO1拨款申请奠定基础。这些目标将通过一个结构化的四部分计划来实现：1)完成临床流行病学科学硕士学位，这是一个在Brian Strom博士的指导下，提高我的研究技能的正式学术课程和教程计划；2)获得一名资深科学家的研究培训和指导，他将作为我的赞助人(Karl Rickels，M.D.)。以及共同赞助者(Edna Foa，Ph.D.)和合作者(Elizabeth Weller，M.D.，Irwin Lucki，Ph.D.，John March，M.P.H.，Brian Strom，M.D.，M.P.H.和Philip C.Kendall，Ph.D.，ABPP)；3)参与正在进行的几项针对情绪和焦虑症儿童和成年人的焦虑和抑郁的精神药理学试验；以及4)设计和执行原创的临床研究治疗方案。符合广泛性焦虑症、分离性焦虑症或焦虑症NOS诊断的8至12岁零11个月的儿童将参加一项随机、双盲、安慰剂对照试验，以评估每天50毫克舍曲林的安全性和有效性(PtN=60)。我还将评估父母的精神病理对儿童的损害程度、精神障碍的发生和药物治疗的反应的调节作用。将对这些家庭进行为期一年的跟踪调查，收集数据进行进一步研究。

This application proposes Moira A. Rynn, M.D. for a Mentored Patient-Oriented Research Career Development Award at the University of Pennsylvania. The aims of this program include: 1) to support my development into an independent research scientist; 2) to support and enhance my development as an investigator in anxiety disorders in children and adolescents; 3) to develop my ability to use my clinical experience to design and execute a protocol that will answer a proposed research question; and 4) to provide the groundwork for the preparation of an RO1 grant application based on the research performed during the award period. These aims will be accomplished through a structured four-part plan: 1) to complete a Master's of Science of Clinical Epidemiology, a program of formal academic courses and tutorials to enhance my research skills, under the supervision of Dr. Brian Strom; 2) to obtain research training and mentoring by a senior scientist who will serve as my sponsor (Karl Rickels, M.D.) as well as by a co-sponsor (Edna Foa, Ph.D) and collaborators (Elizabeth Weller, M.D., Irwin Lucki, Ph.D., John March, M.D., M.P.H., Brian Strom, M.D., M.P.H., and Philip C. Kendall, Ph.D., ABPP); 3) to participate in several ongoing psychopharmacological trials for anxiety and depression in both children and adults in the Mood and Anxiety Disorders Section; and 4) to design and execute an original clinical research treatment protocol. Children aged 8 to 12 years and 11 months who meet the diagnosis of generalized anxiety disorder, separation anxiety disorder, or anxiety disorder nos will enter a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of 50 mg sertraline per day (Pt N = 60). I also will evaluate the moderating effect the presence of parental psychopathology has on the child's level of impairment, onset of disorder and response to medication treatment. Families will be followed for one year to collect for further research.